Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Orexin

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Harmony Starts First-In-Human Study Of Orexin 2 Agonist BP1.15205
    Harmony Starts First-In-Human Study Of Orexin 2 Agonist BP1.15205

    19 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251119313237/en/Harmony-Biosciences-Announces-Initiation-of-First-In-Human-Study-With-Potential-Best-In-Class-Orexin-2-Receptor-Agonist-BP1.15205-for-Central-Disorders-of-Hypersomnolence

    BUSINESSWIRE
    19 Nov 2025
    Share Share
    Alkermes Pushes Narcolepsy Program to Phase 3 With Mid-Stage Data
    Alkermes Pushes Narcolepsy Program to Phase 3 With Mid-Stage Data

    13 Nov 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/alkermes-pushes-narcolepsy-program-to-phase-iii-with-highly-competitive-mid-stage-data

    BIOSPACE
    13 Nov 2025
    Share Share
    Takeda, Alkermes Reveal Narcolepsy Rivals Amid Intensifying Race
    Takeda, Alkermes Reveal Narcolepsy Rivals Amid Intensifying Race

    08 Sep 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/takeda-alkermes-lift-lid-rival-narcolepsy-hopefuls-race-fda-heats

    FIERCE BIOTECH
    08 Sep 2025
    Share Share
    Takeda To Present Additional Data On TAK-861 For Narcolepsy
    Takeda To Present Additional Data On TAK-861 For Narcolepsy

    19 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240919392083/en

    BUSINESSWIRE
    19 Sep 2024
    Share Share
    Nxera's Partner Centessa Reports Positive Data For Novel Orexin Agonist
    Nxera's Partner Centessa Reports Positive Data For Novel Orexin Agonist

    11 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/11/2944350/0/en/Nxera-Pharma-s-Partner-Centessa-Announces-Positive-Interim-Phase-1-Clinical-Data-with-its-Novel-Orexin-Receptor-2-OX2R-Agonist-ORX750-in-Acutely-Sleep-Deprived-Healthy-Volunteers.html

    GLOBENEWSWIRE
    11 Sep 2024
    Share Share
    Centessa Reports Positive ORX750 Phase 1 Interim Data
    Centessa Reports Positive ORX750 Phase 1 Interim Data

    10 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/10/2943494/0/en/Centessa-Announces-Positive-Interim-Phase-1-Clinical-Data-with-its-Novel-Orexin-Receptor-2-OX2R-Agonist-ORX750-in-Acutely-Sleep-Deprived-Healthy-Volunteers.html

    GLOBENEWSWIRE
    10 Sep 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.